Updates and news related to prostate cancer:
There is a reason it is not considered a standard-of-care treatment by most national and international guidelines.
An article from Us TOO International Hot SHEET
miR Scientific Announces FDA Breakthrough Device Designation for Its Prostate Cancer Liquid Biopsy Test
The Company's miR Sentinel™ Prostate Test is a new method to analyze small non-coding RNAs (sncRNA) derived from a simple, non-invasive urine specimen from age-eligible men.
Gallium 68 PSMA PET challenging certain guidelines?
An international research team has discovered a principle that explains the metastasizing of prostate cancer.
Findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer.
Darolutamide Prolongs Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
From Renal & Urology News, Prostate Cancer Advisor
From a report appearing on the US Department of Health and Human Services Effective Health Care page
Adding Carboplatin to chemotherapy regimens for metastatic-castrate resistant prostate cancer in post-second generation hormone therapy setting
Watch this UroToday video: Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer, with Michael Hofman